What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects
AustraliaLongevity June 20, 2025, 10:52am #429 What kind of junk
Well-crafted Go-to-Market strategy With a large self-pay market, the need for differentiated direct-to-consumer engagement models will become more prevalent as a distinct yet complementary approach to traditional payer-driven models
Following comprehensive evaluations in 20132014, both agencies concluded that available evidence did not support a causal association between these medications and pancreatic cancer
Another red flag is any source that frames an injection as effortless or as a substitute for the fundamentals of nutrition, activity, and medical follow-up